drugset / Trial / NCT04176848
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Phase 2
Active not recruiting
15 enrolled
Canadian Cancer Trials Group
AstraZeneca · collabUniversity Health Network, Toronto · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer.
Timeline
- Start
- 2020-08-10
- Primary completion
- 2022-09-15
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | OCIFISERTIB | Small molecule | 32 mg | Oral |